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Abstract: Calibration 2.000 was initiated 20 years ago for 
standardization and harmonization of medical tests. The 
program also intended to evaluate adequate implementa-
tion of the In Vitro Diagnostics (IVD) 98/79/EC directive, 
in order to ensure that medical tests are fit-for-clinical 
 purpose. The Calibration 2.000 initiative led to ongoing 
verification of test standardization and harmonization 
in the Netherlands using commutable external quality 
assessment (EQA)-tools and a type 1 EQA-design, where 
feasible. National support was guaranteed by involving 
all laboratory professionals as well as laboratory techni-
cians responsible for EQA and quality officers. A category 
1 EQA-system for general chemistry analytes, harmonizers 
for specific analytes like hGH and IGF-1, and commutable 
materials for other EQA-sections have been developed and 
structurally introduced in the EQA-schemes. The type 1 
EQA-design facilitates the dialogue between individual 
specialists in laboratory medicine and the IVD-industry 
to reduce lot-to-lot variation and to improve standardiza-
tion. In such a way, Calibration 2.000 sheds light on the 
metrological traceability challenges that we are facing 
and helps the laboratory community to get the issues on 
the table and resolved. The need for commutable true-
ness verifiers and/or harmonizers for other medical tests 
is now seen as paramount. Much knowledge is present 
in the Netherlands and for general chemistry, humoral 
immunology and protein chemistry, a few endocrinology 
tests, and various therapeutic drug monitoring (TDM) 
tests, commutable materials are available. Also the multi 
sample evaluation scoring system (MUSE) and the cat-
egory 1 EQA-design offer many possibilities for permanent 
education of laboratory professionals to further improve 
the between and within laboratory variation and the test 
equivalence.
Keywords: equivalence; harmonization; quality; stand-
ardization; traceability.
Introduction
Medical diagnosis and treatment should be comparable 
for patients across physicians, health care centers and 
countries. Medical test results are paramount in diag-
nosis and monitoring of treatment in a large majority of 
medical decisions. According to the In Vitro Diagnostics 
(IVD) directive 98/79/EC and ISO 17511:2003 medical test 
results should be traceable to standards of higher order in 
order to allow equivalency of test results between instru-
ments as well as between laboratories and countries. 
Equivalence can be defined as agreement among results 
of a laboratory test within the clinically meaningful limits. 
Clinically meaningful limits are defined as the maximum 
degree of variability in results of laboratory tests that 
allows optimal patient care.
Equivalence of laboratory data is important not only 
within laboratories between instruments, but also in time, 
when monitoring patients. As we live in a global world, 
equivalence in reported concentration levels and in units 
used is needed for unequivocal diagnosis and medical 
decision making. In addition when patients are trans-
ferred from one center to another, equivalence of data is 
essential. Test imprecision and bias both should fulfill 
predefined analytical performance criteria derived from 
either clinical outcome or biological variation, to guar-
antee that the test is fit-for-clinical purpose [1, 2]. Units 
should adhere to the BIPM/IFCC agreed International 
System (SI) of units. Comparable diagnoses and treat-
ments require equivalence of laboratory data. To that end 
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bias, imprecision and tolerance criteria should be based 
on agreed models for analytical performance to enable 
better patient outcome.
Equivalence is needed in all disciplines of laboratory 
medicine, including general chemistry, endocrinology, 
immunology, hematology, coagulation, therapeutic drug 
monitoring (TDM), virology and others.
The Calibration 2000 program was initiated in 1998 
by Rob Jansen, at the 25th anniversary of SKML, the 
Dutch external quality assessment (EQA)-organization, 
now 20  years ago [3, 4]. The program aimed at national 
standardization of medical tests (first choice) whenever 
feasible, and at harmonization (second best) in case that 
standardization was not feasible. Standardization is the 
situation when patient results are equivalent between 
measurement procedures and calibration is traceable to 
SI by use of a reference measurement procedure. Har-
monization can be defined as a process that reduces the 
variability of results of a laboratory measurement proce-
dure to a level within the clinically meaningful limits. Six 
SKML EQA-sections were involved from the beginning. 
It started as a national initiative aiming at equivalence 
of laboratory test results [5, 6]. Fifteen years later the 
program was renamed Calibration 2.000 to emphasize 
that the program entered a second phase after achieving 
its first successes, without loosing its original ambition 
and aiming at standardization or, if not possible, harmo-
nization of tests at the global level. The Calibration 2.000 
program that has been developed through the past two 
decades is summarized in Figure  1 and encompasses a 
unified, national EQA-approach across sections based on 
a nationally developed toolbox at MCA Winterswijk, an 
ISO 13485 accredited EQA-material production center, to 
reach equivalence of medical test results. It includes three 
principal components:
1. Development of value-assigned, commutable EQA-
materials, covering clinically relevant concentration 
ranges, structurally embedded in the national EQA-
surveys in combination with a tolerance limit system 
based on the Stockholm conference hierarchy (previ-
ously) and the Milan hierarchy (currently) for analyti-
cal performance specifications. These EQA-materials 
are considered as “holy grail” tools and are used as 
trueness verifiers in the case of SI-traceable tests, to 
measure unequivocally the analytical performance of 
SI-standardized tests.
2. Development of a fair scoring system to analyze con-
formity of tests to preset analytical performance cri-
teria. The scoring system comprises a multi sample 
evaluation (MUSE) EQA system, used in combination 
with trueness verifiers (see 1).
3. Prioritized standardization/harmonization projects to 
maintain good quality and to improve poor ones. The 
projects included standardization where attainable, 
and harmonization in all other situations.
Pre-requisites for Calibration 2.000
The approaches used were comparable ‘avant la lettre’ 
to the integrated harmonization protocol described in 
the toolbox of technical procedures for harmonization at 
http://www.harmonization.net/media/1004/tool_box_ 
2013.pdf.
Figure 1: Calibration 2.000 approach to reach equivalence of 
medical test results.
The essential parts of the toolbox are color coded. All items are 
covered by Calibration 2.000. Milan hierarchy from [7]; MUSE 
scoring system from [8]. EQA, external quality assessment; JCTLM, 
Joint Committee on Traceability in Laboratory Medicine; MUSE, 
multi sample evaluation; TEa, total error allowable. Harmonization 
projects conform [9].
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Standardization and harmonization projects were 
 prioritized based on unmet clinical needs and feasibility. 
The ultimate goal of Calibration 2.000 is to contribute to 
better patient care by delivering the right test result for 
the right patient at the right time. Accurate results are key 
for adequate patient care in which laboratory data play 
a major role, which is the case in the majority of medical 
decisions (70% rule). To that end, metrological traceability 
of laboratory data according to ISO 17511:2003 is pertinent.
For correct interpretation of test results, matching 
clinical reference intervals and decision limits are key in 
combination with SI-units whenever feasible. Absolute 
concentrations are often used in clinical decision making 
(e.g. cholesterol, creatinine or derived parameters, thyroid 
stimulating hormone, glucose) whereas interlaboratory 
and intralaboratory differences, especially differences in 
analytical set-points, can markedly affect the clinical inter-
pretation of tests [10]. This also holds for reference inter-
vals. The use of standardized reference intervals, decision 
limits and SI-units is still debated at the international level 
but currently gets attention from European Federation 
of Clinical Chemistry and Laboratory Medicine (EFLM) 
working groups. However, standardization of units should 
not be controversial as the use of different units for results 
of the same analyte can lead to clinical misinterpretation 
and patient harm [11]. In the Netherlands, the discussion 
on the necessity of molar standardization started in the 
1960s and led at that time to a controversy between inter-
nal medicine doctors and specialists in laboratory medi-
cine, described in the Blind Mole [12]. Since then, Dutch 
medical laboratories are nationwide using SI-units.
Definition of preset analytical performance  criteria 
for the needed level of equivalence were obtained at first 
from the Stockholm conference on strategies to set global 
quality specifications in laboratory medicine [13], and 
more recently from the 1st Strategic Conference of the EFLM 
on defining analytical performance  specifications [7]. 
The Milan conference criteria based on clinical outcome 
studies (Model 1) and biological variation (Model 2) were 
the preferred models. State of the art based criteria were 
considered second best.
Tools developed for the Calibration 2.000 program 
were commutable trueness verifiers or harmonizers and 
a targeting system. Standardization or harmonization can 
only be reached when targeted commutable materials are 
available for trueness verification. The development of 
such materials was considered as the ‘Holy Grail’ of the 
Calibration 2.000 program. As well, a toolbox of technical 
procedures to be considered for developing a process to 
achieve harmonization or standardization of measurands 
formed the basis.
In the program, participating reference  laboratories 
for enzymes, lipids, PT/INR and HbA1c are encouraged 
to apply for ISO 15195 and ISO 17025 accreditation in 
order to get their reference measurement procedures 
internationally recognized and Joint Committee for 
Traceability in Laboratory Medicine (JCTLM)-listed. The 
development of new candidate reference methods is 
also recommended.
Calibration 2.000 is a national endeavor and is pro-
gressed by joint effort and collaboration among different 
laboratory specialisms after creating national support. 
Dutch laboratory specialists are excellent organizers, firm 
in their principles, consensus oriented and scientifically 
engaged. The EQA-sections involved in standardization/
harmonization are all occupied by volunteering labora-
tory professionals who want to push standardization and 
harmonization forward, for the sake of better patient care 
with the focus being on quality. Also, medical laborato-
ries are mostly led by professionals who are specialists in 
laboratory medicine and carry end-responsibility for the 
services of medical laboratories.
Education is a major aspect of Calibration 2.000 
focused on specialists in laboratory medicine and medical 
laboratories. All SKML sections have closed quarterly 
meetings but share expertise during yearly  conferences 
attended by specialists in laboratory medicine and also 
by technicians and quality officers involved with EQA. The 
Calibration 2.000 steering committee has biannual meet-
ings which provide a podium for aligning  standardization 
efforts and sharing expertise. Education consists of lectures, 
courses, and symposia on topics such as  standardization, 
harmonization, method  standardization, validation proce-
dures and explanation of EQA results. Also the lay out and 
parameterization of the EQA system contributes to educa-
tion, e.g. the method definition for enzymes is restricted to 
two method groups, for methods that are either IFCC trace-
able or not. This gives laboratory professionals insight and 
triggers them to opt for IFCC-traceability.
Toolbox
Tools to reach equivalence are (1) commutable trueness 
verifiers and harmonizers, (2) value assignment and (3) 
checks.
1. Commutable materials were produced from fresh 
frozen patient samples. Commutability was assessed 
originally in a twin study design [14] and more recently 
according to CLSI EP 30A (formerly C53-A) [15].
2. Value assignment of the materials was done accord-
ing to the traceability chain using internationally 
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recognized reference methods, reference materials 
and reference laboratories. Bias and imprecision cri-
teria are derived from the Milan conference models. 
In addition the Six Sigma metric was introduced as a 
measure of allowable error.
3. Checks to analyze conformity to the preset crite-
ria were constituted in two systems, (1) an ongoing 
national EQA scheme using multi sample evaluation, 
and (2) provision of trueness verification sample sets 
for individual laboratories for local analytical perfor-
mance checks.
With the above described approach and toolbox for stand-
ardization/harmonization of measurands, the Dutch EQA 
scheme organization SKML established a Category 1 EQA 
system [8, 16], according to the criteria described in the 
‘Roadmap to Harmonization’ paper [17, 18]. According to 
the definition of a Category 1 EQA scheme [18] the SKML 
scheme uses commutable native sera with value assign-
ment by reference methods and allows for verification 
of trueness and precision of IVD tests based on prede-
fined tolerance limits of measurement errors to evaluate 
whether medical tests are fit-for-purpose [19]. It incorpo-
rates the following:
1. Trueness verification materials are offered to labora-
tories for validating/verifying new or reset methods or 
instruments.
2. Analytical performance is assessed by the MUSE 
scoring system [8]. The system assesses both the 
performance of participating laboratories and their 
 methods. Poor (and adequate) performance can result 
from poor (and adequate) laboratory performance or 
from the method performance. For example, the Jaffe 
methods for creatinine perform poorly and should be 
replaced for more adequate performance of the labo-
ratory [20, 21]. Also the suitability of the analytical 
performance of current tests in medical laboratories, 
in the light of guidelines for diabetes and ischemic 
heart disease, was questioned [22].
3. Improvement of trueness and imprecision was and is 
driven by successive standardization projects, where 
attainable, or otherwise harmonization projects both 
nationally and internationally.
The Calibration 2.000 activities catalyzed the trans-
formation of the Dutch SKML from a traditional EQA-
organization with a peer group method approach to an 
EQA-organization that embedded the metrological tracea-
bility and commutability concepts, in line with upcoming 
IVD regulations, ISO-guidelines and international stand-
ardization efforts such as those coordinated by JCTLM 
and the International Federation of Clinical  Chemistry 
and Laboratory Medicine (IFCC) in the last 20  years. 
Based on this national and holistic approach, in combi-
nation with a well thought out toolbox and EQA-design 
for harmonization of measurands, the current SKML-
EQAS gives specialists in laboratory medicine actionable 
information about test performance. The toolbox and 
Calibration 2.000 approach to achieve equivalence of test 
results are summarized in Figure 1. Most items were set up 
in the program itself. In Figure 1 focus is on analytes for 
which reference methods and/or reference materials are 
available. For analytes where these are not in place steps 
towards harmonization are being set in line with ISO 17511 
(under development) in which a special harmonization 
chain will be described. Presently in the EQA schemes 
expert values are being used as target values rather than 
consensus values. Where no such target value is available 
scoring is omitted in the scheme.
Contributors to greater harmonization
Equivalence of laboratory data is pertinent for accurate 
diagnosis and treatment of patients. The perception of 
patients and medical doctors regarding medical labo-
ratory services is that diagnostic laboratories deliver 
accurate test results, which guarantee an unequivocal 
and comparable risk classification, diagnosis,  treatment 
and patient outcome across hospitals. External quality 
assurance programs, which structurally evaluate labo-
ratory test performance, demonstrate that this per-
ception is questionable if not wrong, even for routine 
medical tests [23].
Standardization and harmonization are hot topics in 
laboratory medicine. Many papers address the issue and 
several initiatives were taken to improve the differences 
seen. In particular the AACC harmonization initiative [17, 
18], initiatives of IFCC and EFLM [24–28] and the instal-
lation of the JCTLM contributed significantly, as did the 
Calibration 2.000 project.
The issue of allowable error has gained much interest. 
The Stockholm conference and later on the Milan confer-
ence contributed much to awareness and agreement on 
the way forward. Clinical outcome studies and particu-
larly biological variation based estimations of allowable 
error are widely accepted [1, 7, 13, 27–29].
The need for sophisticated EQA was clearly indi-
cated [18]. In Calibration 2.000 a Category 1 EQA scheme 
was developed using commutable samples that were 
value assigned with reference methods and covering 
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the concentration range of interest, and using  biological 
variation based trueness and imprecision tolerance 
limits including Six Sigma metric [8, 16]. The devel-
opment of commutable samples made it possible to 
perform national and international studies on stand-
ardization and harmonization. Jansen and Jansen [30], 
Boerma et al. [31] and Jansen et al. [32] showed already 
in the 1980s and 1990s that harmonization is necessary 
and standardization should be possible, though the 
materials used were insufficient and lacked commut-
ability. The development of such materials, the value 
assignment by reference laboratories and establishment 
of Category 1 EQA schemes, make it possible at present 
to really assess whether the metrological traceability 
concept is implemented in an adequate way so that 
test standardization/harmonization is achieved. Jansen 
et al. [33] showed this was not the case even for serum 
enzymes.
Implementation of harmonization 
activities across disciplines
It was very encouraging that Calibration 2.000  was 
embraced by several medical laboratory disciplines. The 
milestones of the program are summarized in Table  1. 
The detailed achievements of the various disciplines 
 participating are summarized below.
General chemistry
Most initiatives for harmonization and standardization 
have been in the field of general chemistry. The develop-
ment of commutable EQA materials [33, 42, 54, 55], the 
first ‘Holy Grail’ materials, made evaluation of interlabo-
ratory differences possible. In the studies it was shown 
that harmonization was achievable for several analytes, 
at first for lipids and also for serum enzymes [42, 43, 54, 
55]. For lipids in national studies interlaboratory varia-
tion was shown in normal lipemic commutable samples 
[42]. The introduction of biological variation based toler-
ance limits made objective judgment of the performance 
of laboratories and methods possible. Wide variation 
with both acceptable and unacceptable performance was 
shown in international studies for lipids, enzymes, cre-
atinine, electrolytes and other analytes [16, 33, 45, 56]. 
The joint project by the national EQA organizers in Italy, 
the Netherlands, Portugal, UK and Spain (INPUtS) [45] 
showed that the analytical performance of 11 of 17 general 
chemistry analytes measured in European medical labo-
ratories met the minimum performance specifications. 
However, only one analyte (creatine kinase) met the desir-
able specifications in all countries and for all manufactur-
ers. There were however, major differences between other 
analytes. There were six analytes for which the minimum 
quality specifications are not met and manufacturers 
should strive to improve their performance for these ana-
lytes. Standardization of enzyme methods towards IFCC 
Table 1: Milestones and deliverables of Calibration 2.000 program from 1998 to 2018.
Year   Milestone   Refs.
1998   Initiation at congress celebrating the 25th anniversary of the Dutch external quality assessment 
(EQA)-organization SKML
  [3–5]
1999   Task Force Calibration 2.000 8 sections of SKML   [6, 34–39]
2001   Twin studies to detect first commutable materials   [14, 40, 41]
2002   First commutable and value-assigned materials for general chemistry   [42, 43]
2005   Nationwide introduction of trueness verification in EQA-scheme, including ongoing commutability 
assessment with native spy material 
  [43, 44]
2006   International enzyme studies   [16, 33, 45]
2008   National harmonization of growth hormone   [34, 46]
2009   National harmonization of fibrinogen, Factor VIIIc, antithrombin   [36, 47, 48]
2010   >60% laboratory standardized for eight general chemistry analytes   [44]
2012   National harmonization of seven enzymes   [44]
2014   Renaming to Calibration 2.000 because of global scope  
2014   Participation in preparational harmonization conference of the American Association for Clinical 
Chemistry (AACC)
  [17, 18]
2015   Introduction of a uniform multi sample evaluation scoring system for all SKML sections   [8, 16]
2015   Commutable material for therapeutic drug monitoring (TDM)   [37, 49]
2017   Development of reference methods/systems for serum apolipoproteins, plasma antithrombin, serum 
free light chains
  [50–53]
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reference measurement procedures (RMPs) has not been 
fully achieved as shown in the INPUtS study. Forty-four 
percent of results of seven enzymes on six platforms failed 
the desirable criterion based on biological variation. It 
requires ongoing efforts. Performance of laboratories and 
tests showed under-performance in several studies, and 
the necessity of better standardization of both methodol-
ogy and calibration materials was stressed [20–23].
HbA1c is another test that needed harmonization [57]. 
Also for HbA1c important results were achieved. An inter-
national HbA1c network has been established for global 
standardization of HbA1c. In the Netherlands, two labo-
ratories operate the international reference method for 
HbA1c and are recognized as certified reference labora-
tories. Practically all Dutch laboratories implemented in 
a coordinated action with clinical societies and patient 
organizations the new units of mmol/mol. The improve-
ment in HbA1c test performance is huge as interlabora-
tory CVs reduced from 30% in the early 1990s to about 
3% in 2017. Stressing necessity is one thing, achieving 
the objectives is another. Figure 2 shows improvements 
reached in analytical performance in the Netherlands for 
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Figure 2: Analytical performance trends for 17 general clinical chemistry parameters between 2005 and 2010.
The analytes are divided in four color coded groups: three color coded groups refer to minerals, substrates and enzymes of which the EQA-
materials have been value assigned with recognized reference methods (n = 13); the red colored group encompasses the parameters that rely 
on consensus means and have not been value assigned with recognized reference methods (n = 4). (A) Evolution of the degree of equivalence 
of test results as indicated by the between-laboratory CV (CV in 2010 is smaller than in 2005 for most analytes). (B) Evolution of the true-
ness component between 2005 and 2010. Criterion for bias is based on deviation from reference value in relation to the biological variation 
desirable criterion [1, 2]. The percentage laboratories that pass the bias criterion is larger in 2010 than in 2005. (C) Evolution of the precision 
component between 2005 and 2010 criterion for imprecision (within-laboratory CV) is based on biological variation desirable criterion [1, 2]. 
The percentage laboratories that pass the CV criterion is about equal in 2010 and 2005. (D) Evolution of total allowable error (TEa) between 
2005 and 2010 Criterion for total error is based on biological variation desirable criterion [1, 2]. The percentage laboratories that pass the TE 
criterion is larger in 2010 than in 2005. For several parameters only 20% pass the TE criterion because of the rather strict biological variation 
criteria particularly for sodium, chloride, calcium and magnesium. (Reprinted from [44], with permission from the publisher Elsevier.)
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enzymes, creatinine and other analytes after running the 
type 1 EQA-program for 5 years [44, 58]. Additional chal-
lenges were demonstrated when lipemic sera were used 
for testing lipid methodology [59] or high glucose sera in 
creatinine analysis [60]. The demonstration of poor per-
formance of non-IFCC traceable methods for enzymes and 
of Jaffe methods for creatinine led to better standardiza-
tion of methodology in the Netherlands [44].
Reference laboratories operating internationally rec-
ognized reference methods exist in the Netherlands for 
serum lipids (the Lipid Reference Laboratory of Erasmus 
University Hospital which is a member of the CRMLN 
operated by CDC), serum enzymes (Dr. Paul F.H. Franck, 
LabWest, The Hague) and HbA1c (Dr. Cas Weykamp, 
Beatrix Hospital Winterswijk, Dr. Erna Lenters, Isala 
 Hospital Zwolle).
Lipid and apolipoprotein standardization
Notwithstanding adequate standardization of direct high-
density lipoprotein cholesterol (HDL-C) and low-density 
lipoprotein cholesterol (LDL-C) tests, it was demonstrated 
at the national level that direct HDL-C and LDL-C tests 
suffer from non-selectivity in hypertriglyceridemic sera, 
leading to significant misclassification rates [59]. As the 
residual cardiovascular risk after reaching the treatment 
goals for LDL-C, blood pressure and diabetes remains high 
(around 70%), alternative (apolipo)protein tests should 
help to unravel cardiovascular disease pathophysiology 
and to select better treatment targets. To that end, an IFCC 
working group on apolipoprotein (APO) standardization 
has been established which should develop a complete 
mass spectrometry based Reference Measurement System 
for multiplex apolipoprotein quantitation and phenotyp-
ing (http://www.ifcc.org/ifcc-scientific-division/sd-work-
ing-groups/wg-apo-ms/). Investigations have been started 
to metrological traceability in mass spectrometry-based 
targeted protein quantitation of the apolipoproteins A-I 
and B100 [61].
Endocrinology, binding assays, vitamins
The issue of harmonization and standardization was 
also recognized in endocrinology and binding assays as 
tumor markers and vitamins. Although reference methods 
exist in the JCTLM database for several steroid hormones, 
mostly based on mass-spectrometry methods, standardi-
zation is still a major problem. There is a lack of commut-
able materials in EQA surveys to check routine tests which 
are often based on immunological methods.
Peptide hormones are even a bigger challenge. A 
special problem in this respect are growth hormone 
(hGH) and insulin like growth factor (IGF-1). The diag-
nosis growth hormone deficiency largely depends on 
the hGH test result. Because of the relevance of growth 
hormone treatment in children with short statue, both 
clinically and financially, between-laboratory harmo-
nization of results is paramount. A practical approach 
in the Netherlands led to such national harmonization 
using a national harmonizer [34, 46, 62]. This initia-
tive is now taken to the international level in an inter-
national IFCC working group on hGH standardization, 
led by Eef Lentjes from the Netherlands (http://www.
ifcc.org/ifcc-scientific-division/sd-working-groups/
growth-hormone-(wg-gh)/).
Today carbohydrate deficient transferrin (CDT) is con-
sidered an important objective indicator of sustained high 
alcohol consumption and is used to support the diagnosis 
of alcohol abuse and dependence in medical and forensic 
settings, including driver’s license withdrawal and rein-
statement [63]. Harmonization of the assay obviously is 
important. The Calibration 2.000 project and co-workers 
of it contributed both to harmonization [64, 65] and to the 
development of a reference method [63].
Another example of an analyte in need of harmoni-
zation is vitamin B6 (pyridoxal/pyridoxal-phosphate). 
van Zelst et  al. [35] showed large within-laboratory 
variation for some methods, and in addition between- 
laboratory variation. The authors suggested that the 
lack of a reference method or suitable certified reference 
 material for the measurement of vitamin B6 in whole 
blood is impeding the standardization or harmonization 
of this assay.
Protein chemistry
In various fields of protein chemistry studies were done 
towards harmonization. Initial studies to find com-
mutable material for serum proteins such as albumin, 
α1-antitrypsin, immunoglobulins and other proteins were 
done in the Netherlands by Klasen et al. [40, 66]. Success-
ful follow-up of the initiative has found application with 
commutable materials, value assigned in the SKML EQA 
system for plasma proteins, but this has not yet been pub-
lished. For other more specific proteins research focuses 
on method robustness and harmonization. For example, 
first steps are underway for hepcidin [67].
The use of NIST SRM 2921 and recombinant 
 cTnI-based serum pools for harmonization was investi-
gated by Cobbaert et al. [50, 68] who found the material 
unstable.
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Coagulation
Harmonization of coagulation data is important in 
 particular for situations including monitoring anticoagu-
lation therapy such as prothrombin time INR, diagnosis 
and monitoring of factor VIII-C, for decision levels of 
fibrinogen, antithrombin and activated partial thrombo-
plastin time. The SKML section on coagulation partici-
pated actively in the Calibration 2.000 project from the 
start and harmonization initiatives were taken for fibrin-
ogen, Factor VIIIc and antithrombin [36, 41, 47, 48, 69]. 
Extensive scientific work on PT/INR standardization was 
done at the Leiden reference laboratory (Dr. Ton van den 
Besselaar), which runs the reference method for INR. PT/
INR standardization activities are currently embedded in 
the Coagulation Reference Laboratory of the Department 
of Clinical Chemistry and Laboratory Medicine, at LUMC, 
which has initiated global standardization of the Manual 
Tilt Tube method for PT/INR standardization. Also, a col-
laboration between the Coagulation Reference Lab in 
Leiden, the international EQA organization for coagula-
tion (ECAT) and IVD-industry has been set up for devel-
oping a mass spectrometry based reference measurement 
system for antithrombin [51].
Therapeutic drug monitoring
Recently the Calibration 2.000 tools and toolbox were also 
applied for standardization of TDM tests. Commutable 
materials were developed for carbamazepine, valproic 
acid and tobramycin [37, 49]. Between-laboratory studies 
showed that some methods were inaccurate. Future 
studies will indicate whether the use of the commutable 
materials could lead to harmonization between laborato-
ries and methods.
Hemocytometry and flow cytometry
Initial studies indicated that commercially available mate-
rials cannot be used as a calibrator for all parameters on all 
of the common hematology analyzers. Most EQA samples, 
however, as prepared and used in the Netherlands, were 
commutable for all parameters and analyzers [70]. Most 
routine parameters including RBC, WBC, platelets and 
Hb are harmonized in the Netherlands. Future studies are 
necessary to show harmonization of the parameters RBC-
distribution width and platelet-distribution width and 
also of WBC subclasses.
For flow cytometry of the parameters HLA-B27, 
CD-45 and CD-34 +  lymphocytes, studies were performed 
and showed inter-laboratory variation [38, 71–74]. The 
 competition with PCR methodology hampered further 
efforts.
Microbiology
Cut-off values in the sense of positive or negative for serol-
ogy parameters could have a clinical impact if there is lack 
of harmonization. Studies were started in this respect in 
line with the early onset of Calibration 2.000 [39, 75]. Also 
in this field further studies are needed to develop com-
mutable materials and promote calibration.
Current Calibration 2.000 projects
Currently the Calibration 2.000 steering committee focuses 
on sustainable contributions to standardization and har-
monization at both the national and international level. 
Some sections are supporting the development of refer-
ence methods for example for standardization of serum 
apolipoproteins C1, C2, C3 and E [76], serum free light 
chains [77], and citrate plasma antithrombin [51]. Also, 
an approach and system for implementing national refer-
ence intervals and decision limits for SI-traceable analytes 
is underway [78]. Finally, as part of continuing education 
SKML EQA sections will start reporting only in the pre-
ferred unit, instead of the unit of choice by the participant.
Lessons learnt from Calibration 2.000
There is worldwide an increasing awareness of the need 
for test standardization and harmonization in medical 
practice [52, 53]. Also, international ISO guidelines includ-
ing ISO 17511, ISO 17025, ISO 15189 and mandatory legisla-
tion such as the IVD directive 98/79/EC and upcoming new 
IVD Regulation in Europe, demand global standardization 
of medical tests, if feasible. Multiple international and 
national communities and stakeholders of medical tests 
have taken initiatives in an attempt to reach test equiva-
lence [3, 17, 52].
Standardization of units and introduction of molar 
units were already realized in the 1970s in the  Netherlands 
[12]. National support for test standardization since 1998 
combined with the striving of SKML and Calibration 2.000 
Steering Committee to develop type 1 EQA schemes across 
several EQA-sections and laboratory disciplines, resulted 
in the development of a permanent infrastructure and 
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powerful toolbox for giving insight into trueness (for 
SI-traceable tests), precision and interlaboratory variation 
of medical tests. The Dutch EQA-design and toolbox allow 
laboratory professionals to act by means of, e.g. tempo-
rary recalibration if inequality of test results has occurred 
and may cause patient harm.
Unfortunately, standardization and harmonization of 
tests is cumbersome for many reasons including regula-
tions that hinder uncomplicated re-standardization and 
harmonization of existing tests (e.g. FDA required test 
re-evaluation after re-calibration). On the other hand, 
notwithstanding successful worldwide realization of for 
example an IFCC reference method system for HbA1c, 
adoption of re-standardized tests is slow at the interna-
tional level as there are still two reference systems (IFCC 
and NGSP) and two units (mmol/mol and %) in place. The 
same holds for the standardization of the serum enzymes: 
there are still IFCC traceable and non IFCC traceable 
enzyme results.
Calibration 2.000  was initiated 20  years ago for 
standardization and harmonization of medical tests. The 
program also intended to evaluate adequate implementa-
tion of the IVD 98/79/EC directive, to ensure that medical 
tests are fit-for-clinical purpose. Figure 3 shows the rela-
tionships between the IVD-industry, SKML-Calibration 
2.000 and the laboratory professionals. The Calibration 
2.000 initiative led to ongoing verification of test stand-
ardization and harmonization in the Netherlands using 
commutable EQA-tools and a type 1 EQA-design, where 
feasible. National support was guaranteed by involving 
all laboratory professionals as well as laboratory techni-
cians responsible for EQA and quality officers. A category 
1 EQA-system for general chemistry analytes, harmonizers 
for specific analytes like hGH and IGF-1, and commutable 
materials for other EQA-sections have been developed and 
structurally introduced in the EQA-schemes. The type 1 
EQA-design facilitates the dialogue between individual 
specialists in laboratory medicine and the IVD-industry to 
reduce lot-to-lot variation and to improve standardization. 
In such a way, Calibration 2.000 sheds light on the met-
rological traceability challenges that we are facing and 
helps the lab community identify the issues and to resolve 
these. The need for commutable trueness verifiers and/or 
harmonizers for other medical tests is now seen as para-
mount. Much knowledge is present in the Netherlands 
and for general chemistry, humoral immunology and 
protein chemistry, a few endocrinology tests, and various 
TDM tests, commutable materials are available. Also the 
MUSE scoring system and the category 1 EQA-design offer 
many possibilities for permanent education of laboratory 
professionals to further improve the between and within 
laboratory variation and the test equivalence.
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Figure 3: Relationship between IVD-industry, SKML Calibration 2.000 and laboratory professionals.
CE-IVD, Conformité Européenne (European conformity) in vitro diagnostics; JCTLM, Joint Committee on Traceability in Laboratory Medicine; 
EQAS, external quality assessment scheme; TEa, total error allowable.
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